Erlotinib Overview Categories 8 Antineoplastics, immunomodulators and drugs used in palliative care8.2 Cytotoxic (anti-neoplastic) drugs Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Erlotinib Manufacturers of Erlotinib Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Erlotinib's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 100 mg100 (100)24 hourlyoralFor non-small cell PANCREATIC cancer, should be taken at least one hour before or two hours after the ingestion of food.150 mg150 (150)24 hourlyPOFor non-small cell LUNG cancer, should be taken at least one hour before or two hours after the ingestion of food. Paedriatic Dosage (20kg) No data regarding the Paedriatic dosage details of Erlotinib is available. Neonatal Dosage (3kg) No data regarding the neonatal dosage details of Erlotinib is available. High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Erlotinib Back to top Manufacturers of Erlotinib in Pakistan Roche Back to top Previous Drug Generic - Next Drug Generic